| Literature DB >> 31062123 |
Andrea Katharina Lindner1, Gert Schachtner1, Eberhard Steiner1, Alexander Kroiss2, Christian Uprimny2, Fabian Steinkohl3, Wolfgang Horninger1, Isabel Heidegger1, Stephan Madersbacher4, Renate Pichler5.
Abstract
PURPOSE: To report on the oncological outcome of organ-sparing surgery (OSS) compared to (total or partial) penectomy regarding recurrence patterns and survival in squamous cell carcinoma (SCC) of the penis.Entities:
Keywords: Follow-up; Organ-preserving surgery; Penile neoplasm; Recurrence; Squamous cell; Survival
Year: 2019 PMID: 31062123 PMCID: PMC6994547 DOI: 10.1007/s00345-019-02793-9
Source DB: PubMed Journal: World J Urol ISSN: 0724-4983 Impact factor: 4.226
Fig. 1Sentinel lymph node biopsy (SLNB) guided by lymphoscintigraphy [39]. In addition to early dynamic imaging (not displayed) following intradermal injection of 40 MBq Technetium-99 m-labelled nanocolloidal albumin (99mTc-Nanocoll®) peritumorally, planar static imaging 60 min post-injection of the pelvis is performed, including combined single-photon-emission tomography with low-dose computed tomography (SPECT/CT) acquisition. On planar image 60 min p.i. apart from the injection site (a green arrow), intense focal tracer uptake is visualized in the right and left pelvic area (a red arrows). On fused SPECT/CT images (b axial slice, red arrows), focal uptake is located in the inguinal region, that corresponded to non-enlarged lymph nodes on low-dose CT (c axial slice, red arrows), representing inguinal SLN. Both SLN were localized intra-operatively with a gamma-probe 1 day after tracer injection and could be surgically removed (d, e). Final histology confirmed pN0
Descriptive patient and histopathological characteristics of the study population (overall and stratified by penile surgical approach), n = 55
| Patients | Treatment | |||
|---|---|---|---|---|
| OSS (%) | (Partial/total) amputation (%) | Total (%) | ||
| 26 | 29 | 55 | ||
| Age* (years) | ||||
| Mean ± SD | 61.1 ± 14 | 68.9 ± 12.2 | 65.2 ± 1 | |
| Median | 62 | 68 | 66 | |
| pT stage**, | ||||
| pTis (%) | 7 (26.9%) | – | 7 (12.7%) | |
| pTa (%) | 7 (26.9%) | 2 (6.9%) | 9 (16.3%) | |
| pT1a (%) | 8 (30.8%) | 2 (6.9%) | 10 (18.2%) | |
| pT1b (%) | 1 (3.8%) | 2 (6.9%) | 3 (5.5%) | |
| pT2 (%) | 3 (11.5%) | 13 (44.8%) | 16 (29.1%) | |
| pT3 (%) | – | 10 (35.55) | 10 (18.2%) | |
| Tumor grade**, | ||||
| Grade 1 | 7 (26.9%) | 4 (13.8%) | 11 (20%) | |
| Grade 2 | 16 (61.6%) | 16 (55.2%) | 32 (58.2%) | |
| Grade 3 | 3 (11.5%) | 9 (31%) | 12 (21.8%) | |
| Clinical lymph node status (cN)**, | ||||
| cN0 | 23 (88.5%) | 21 (72.4%) | 44 (80%) | |
| cN1/N2 | 3 (11.5%) | 8 (27.6%) | 11 (20%) | |
| cN3 | – | – | – | |
| DSNB/miLND**, | 9 (34.65%) | 11 (37.9%) | 20 (36.7%) | |
| rLAD**, | 3 (11.5%) | 12 (41.4%) | 15 (27.3%) | |
| pN status (DSNB/miLAD)**, | ||||
| pN0 | 9 (100%) | 7 (63.6%) | 16 (29.1%) | |
| pN1 | – | 4 (36.4%) | 4 (7.2%) | |
| pN2/pN3 | – | – | – | |
| pN status (rLAD)**, | ||||
| pN0 | 2 (75%) | 7 (58.3%) | 9 (16.4%) | |
| pN1 | 1 (25%) | 5 (41.7%) | 6 (10.9%) | |
| pN2/pN3 | – | – | – | |
| Local recurrence**, | ||||
| Yes | 11 (42.3%) | 3 (10.3%) | 14 (25.5%) | |
| No | 15 (57.7%) | 26 (89.7%) | 41 (74.5%) | |
| Regional recurrence**, | ||||
| Yes | 1 (3.8%) | 3 (10.3%) | 4 (7.2%) | |
| No | 25 (96.2%) | 26 (89.7%) | 51 (92.7%) | |
| Distant metastasis**, | ||||
| Yes | 2 (7.7%) | 4 (13.8%) | 6 (10.9%) | |
| No | 24 (92.3%) | 25 (86.2%) | 49 (89.1%) | |
Bold values indicate p < 0.05 was considered as statistically significant
OSS organ-sparing surgery, DSNB dynamic sentinel-node biopsy, miLND modified inguinal lymph node dissection, rLAD radical inguinal lymphadenectomy
p values were calculated by Mann–Whitney U test* and Pearson chi-square test**
Fig. 2Kaplan–Meier survival curves. a Local recurrence-free survival (RFS), b (lymphatic and hematogenous) metastasis-free survival and c overall survival (OS) in months according to the type of penile surgical approach (OSS vs. penile amputation). p values by log-rank test; *p < 0.05; **p < 0.01; ***p < 0.001